Cellectar Biosciences PE Ratio 2010-2025 | CLRB
Current and historical p/e ratio for Cellectar Biosciences (CLRB) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cellectar Biosciences PE ratio as of June 06, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Cellectar Biosciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-06 | 0.36 | 0.00 | |
| 2025-03-31 | 0.32 | $-0.73 | 0.00 |
| 2024-12-31 | 0.30 | $-1.33 | 0.00 |
| 2024-09-30 | 2.14 | $-1.72 | 0.00 |
| 2024-06-30 | 2.50 | $-2.53 | 0.00 |
| 2024-03-31 | 3.98 | $-3.08 | 0.00 |
| 2023-12-31 | 2.77 | $-3.10 | 0.00 |
| 2023-09-30 | 2.64 | $-3.25 | 0.00 |
| 2023-06-30 | 1.95 | $-3.32 | 0.00 |
| 2023-03-31 | 1.43 | $-3.81 | 0.00 |
| 2022-12-31 | 1.71 | $-4.05 | 0.00 |
| 2022-09-30 | 3.36 | $-4.50 | 0.00 |
| 2022-06-30 | 4.04 | $-4.22 | 0.00 |
| 2022-03-31 | 6.88 | $-4.10 | 0.00 |
| 2021-12-31 | 6.64 | $-4.40 | 0.00 |
| 2021-09-30 | 9.25 | $-4.10 | 0.00 |
| 2021-06-30 | 11.90 | $-4.60 | 0.00 |
| 2021-03-31 | 16.10 | $-6.10 | 0.00 |
| 2020-12-31 | 20.80 | $-9.00 | 0.00 |
| 2020-09-30 | 12.40 | $-11.60 | 0.00 |
| 2020-06-30 | 12.80 | $-14.30 | 0.00 |
| 2020-03-31 | 13.33 | $-16.30 | 0.00 |
| 2019-12-31 | 22.50 | $-19.70 | 0.00 |
| 2019-09-30 | 20.00 | $-16.40 | 0.00 |
| 2019-06-30 | 21.80 | $-28.70 | 0.00 |
| 2019-03-31 | 23.50 | $-41.00 | 0.00 |
| 2018-12-31 | 15.50 | $-54.40 | 0.00 |
| 2018-09-30 | 30.00 | $-3,454.40 | 0.00 |
| 2018-06-30 | 62.00 | $-3,463.90 | 0.00 |
| 2018-03-31 | 113.50 | $-3,470.00 | 0.00 |
| 2017-12-31 | 137.00 | $-3,473.00 | 0.00 |
| 2017-09-30 | 167.00 | $-107.00 | 0.00 |
| 2017-06-30 | 163.00 | $-124.00 | 0.00 |
| 2017-03-31 | 227.00 | $-150.00 | 0.00 |
| 2016-12-31 | 122.00 | $-35.00 | 0.00 |
| 2016-09-30 | 271.00 | $-1.00 | 0.00 |
| 2016-06-30 | 344.00 | $-208.00 | 0.00 |
| 2016-03-31 | 341.83 | $-459.00 | 0.00 |
| 2015-12-31 | 735.00 | $-850.00 | 0.00 |
| 2015-09-30 | 1970.00 | $-1,070.00 | 0.00 |
| 2015-06-30 | 2880.00 | $-920.00 | 0.00 |
| 2015-03-31 | 3110.00 | $-1,350.00 | 0.00 |
| 2014-12-31 | 3090.00 | $-2,050.00 | 0.00 |
| 2014-09-30 | 2220.00 | $-3,230.00 | 0.00 |
| 2014-06-30 | 6390.00 | $-6,130.00 | 0.00 |
| 2014-03-31 | 7800.00 | $-6,200.00 | 0.00 |
| 2013-12-31 | 7400.00 | $-6,600.00 | 0.00 |
| 2013-09-30 | 7200.00 | $-6,200.00 | 0.00 |
| 2013-06-30 | 9200.00 | $-4,400.00 | 0.00 |
| 2013-03-31 | 9210.00 | $-4,800.00 | 0.00 |
| 2012-12-31 | 14800.00 | $-4,600.00 | 0.00 |
| 2012-09-30 | 21000.00 | $-4,800.00 | 0.00 |
| 2012-06-30 | 23800.00 | $-5,000.00 | 0.00 |
| 2012-03-31 | 17000.00 | $-5,800.00 | 0.00 |
| 2011-12-31 | 8800.00 | $-11,400.00 | 0.00 |
| 2011-09-30 | 25400.00 | $-11,800.00 | 0.00 |
| 2011-06-30 | 26000.00 | $-10,800.00 | 0.00 |
| 2011-03-31 | 54468.00 | $-70,338.45 | 0.00 |
| 2010-12-31 | 79254.00 | $-2,000.00 | 0.00 |
| 2010-09-30 | 159120.00 | $-800,399.90 | 0.00 |
| 2010-06-30 | 321300.00 | $-1,015,384.50 | 0.00 |
| 2010-03-31 | 556920.00 | $-1,353,846.05 | 0.00 |
| 2009-12-31 | 1000000.00 | $-1,630,769.10 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.017B | $0.000B |
| Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.407B | 27.95 |
| Boston Scientific (BSX) | United States | $151.037B | 37.81 |
| Stryker (SYK) | United States | $146.527B | 30.64 |
| EssilorLuxottica (ESLOY) | France | $129.703B | 0.00 |
| Medtronic (MDT) | Ireland | $112.146B | 15.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.313B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.844B | 28.38 |
| ResMed (RMD) | United States | $36.979B | 27.78 |
| Agilent Technologies (A) | United States | $32.895B | 21.44 |
| GE HealthCare Technologies (GEHC) | United States | $32.794B | 15.57 |
| Terumo (TRUMY) | Japan | $26.561B | 34.50 |
| Koninklijke Philips (PHG) | Netherlands | $22.051B | 15.85 |
| Insulet (PODD) | United States | $21.941B | 86.12 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.277B | 11.74 |
| Baxter (BAX) | United States | $15.529B | 11.59 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.253B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.430B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.971B | 20.78 |
| Lantheus Holdings (LNTH) | United States | $5.642B | 14.23 |
| Prestige Consumer Healthcare (PBH) | United States | $4.203B | 18.78 |
| Perrigo (PRGO) | Ireland | $3.596B | 9.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.385B | 15.42 |
| ICU Medical (ICUI) | United States | $3.275B | 24.15 |
| Envista Holdings (NVST) | United States | $3.174B | 26.38 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $1.997B | 13.73 |
| LeMaitre Vascular (LMAT) | United States | $1.901B | 42.49 |
| AtriCure (ATRC) | United States | $1.730B | 0.00 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.201B | 12.19 |
| Neogen (NEOG) | United States | $1.131B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.126B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.100B | 24.74 |
| Kestra Medical Technologies (KMTS) | United States | $1.063B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.976B | 12.48 |
| InMode (INMD) | Israel | $0.895B | 9.02 |
| Capricor Therapeutics (CAPR) | United States | $0.650B | 0.00 |
| Evolus (EOLS) | United States | $0.647B | 0.00 |
| CeriBell (CBLL) | United States | $0.647B | 0.00 |
| Owens & Minor (OMI) | United States | $0.619B | 5.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.584B | 0.00 |
| Valneva SE (VALN) | France | $0.515B | 0.00 |
| Surmodics (SRDX) | United States | $0.420B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.408B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.76 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.322B | 57.20 |
| Canopy Growth (CGC) | Canada | $0.313B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 11.87 |
| Sanuwave Health (SNWV) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.221B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Biote (BTMD) | United States | $0.210B | 5.89 |
| Quanterix (QTRX) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 52.25 |
| High Tide (HITI) | Canada | $0.193B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.86 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Exagen (XGN) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 16.54 |
| Jin Medical (ZJYL) | China | $0.120B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.59 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.14 |
| Nephros (NEPH) | United States | $0.036B | 48.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |